Haemacure Corp.
Industry
- Biotechnology
- Medical Devices
- Surgical Equipment & Devices
- Surgical Sealants
- Biomaterials
- Surgical Equipment & Devices
Latest on Haemacure Corp.
Haemacure has put itself up for sale while its hunt for financing continues to be unsuccessful. The Canadian company, which has been seeking cash since the third quarter of last year, will also suspen
The Canadian biotherapeutics company Haemacure has appointed Dr Thomas Lynch to its board of directors. Dr Lynch brings 15 years experience as a research scientist in public, academic and private
Renovo's scar-healing treatment Juvista (human recombinant TGF beta ) has succeeded in a Phase II study, but details of US development plans for the product have disappointed analysts and investors. R
Renovohas received positive feedback from the EU's CHMPregarding its plans for Phase III development of the scar-reduction treatment Juvista. The UK-based company, whose products are focussed on scar